Filtered By:
Cancer: Cancer
Countries: Ireland Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 12 results found since Jan 2013.
Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
ConclusionFor patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Source: Clinical and Translational Oncology - April 23, 2023 Category: Cancer & Oncology Source Type: research
Osteoporotic fracture admissions compared to other major medical admissions in Irish public hospitals
ConclusionOsteoporotic fractures represent a large and rapidly increasing illness burden amongst older Irish adults, with substantial care requirements and the resulting onus on our healthcare system. Urgent action is needed to address this public health issue and the services for those at risk of fracture.
Source: Archives of Osteoporosis - December 17, 2022 Category: Orthopaedics Source Type: research
The final puff: Can New Zealand quit smoking for good?
Smoking kills. Ayesha Verrall has seen it up close. As a young resident physician in New Zealand’s public hospitals in the 2000s, Verrall watched smokers come into the emergency ward every night, struggling to breathe with their damaged lungs. Later, as an infectious disease specialist, she saw how smoking exacerbated illness in individuals diagnosed with tuberculosis and HIV/AIDS. She would tell them: “The best thing you can do to promote your health, other than take the pills, is to quit smoking.”
Verrall is still urging citizens to give up cigarettes—no longer just one by one, but by the thousands. As New...
Source: ScienceNOW - December 9, 2022 Category: Science Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Obesity and cardiovascular risk in an oncology day ward population
ConclusionsWe observed similar or lower rates of obesity and CV risk factors in this cohort compared to the general adult Irish population. The average predicted risk of developing CV disease in this grp was moderate to high. This can have significant future implications with regard to cancer survivorship, disease recurrence and suitability for further oncological treatments.
Source: Irish Journal of Medical Science - December 18, 2018 Category: General Medicine Source Type: research
Medtronic Finds Another Value-Based Care Partner
Dublin, Ireland-based Medtronic continues to lead the charge toward value-based care with a new five-year strategic partnership with Lehigh Valley Health Network (LVHN), an eight-hospital network in Northeastern Pennsylvania. The partnership is aimed at developing innovative, sustainable, and integrated value-based solutions to improve healthcare outcomes for LVHN's patients.
The partnership will create programs that span more than 70 major medical conditions, with the goal of positively impacting as many as 500,000 patients and reducing their cost of care by $100 million.
The organizations said the partnership will leve...
Source: MDDI - February 28, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Medical Device Business Source Type: news
KCA Board Member to Participate in LIVESTRONG ® Global Cancer Summit in Dublin, Ireland
FOR IMMEDIATE RELEASE Kidney Cancer Association CONTACT NAME: Carrie Konosky PHONE NUMBER: 847-655-4495 x104 EMAIL ADDRESS: ckonosky@kidneycancer.org Eric Perakslis, Kidney Cancer Association Board Member, Selected to Participate in Premiere LIVE ST...
Source: Kidney Cancer Association - July 17, 2009 Category: Urology & Nephrology Source Type: news
